Glenmark Pharmaceuticals U.S. > News

News

Press Releases

Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.

Glenmark Pharmaceuticals Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310 Compared to the Reference Product Omalizumab

July 25, 2018

Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet

July 20, 2018

Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet

July 17, 2018

The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals’ Manufacturing Facility in Monroe, North Carolina

June 18, 2018

Glenmark receives ANDA approval for HAILEY 1.5-30 and HAILEY Fe 1.5-30 Tablets

June 6, 2018

News

Search Result :-

Is an investigational new drug that has not been approved for commercial distribution in the United States.

July 25, 2018
Glenmark Pharmaceuticals Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310 Compared to the Reference Product Omalizumab

July 20, 2018
Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet

July 17, 2018
Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet

June 18, 2018
The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals’ Manufacturing Facility in Monroe, North Carolina

June 6, 2018
Glenmark receives ANDA approval for HAILEY 1.5-30 and HAILEY Fe 1.5-30 Tablets

US Media Contact

For media inquiries only, please contact Corporate Communications.
uscomms@glenmarkpharma.com

Investor Relations

For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.

POTASSIUM CHLORIDE EXTENDED RELEASE CAPSULES 750mg RECALL REIMBURSEMENT POLICY

Over-the-counter (OTC)

ACCESSIBLE PRODUCTS

Who We Are

Injectables

OUR GROWING LINE